Apyx Medical Corporation [APYX] is 10.68% higher this YTD. Is it still time to buy?

Apyx Medical Corporation [NASDAQ: APYX] loss -0.77% on the last trading session, reaching $2.59 price per share at the time. The company report on January 10, 2023 that Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2022.

Apyx Medical Corporation represents 34.57 million in outstanding shares, while the company has a total market value of $90.29 million with the latest information. APYX stock price has been found in the range of $2.55 to $2.67.

If compared to the average trading volume of 346.20K shares, APYX reached a trading volume of 527631 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Apyx Medical Corporation [APYX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for APYX shares is $7.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on APYX stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Lake Street have made an estimate for Apyx Medical Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 20, 2022. While these analysts kept the previous recommendation, Dougherty & Company raised their target price from $12 to $9. The new note on the price target was released on April 02, 2019, representing the official price target for Apyx Medical Corporation stock.

The Average True Range (ATR) for Apyx Medical Corporation is set at 0.20, with the Price to Sales ratio for APYX stock in the period of the last 12 months amounting to 1.85. The Price to Book ratio for the last quarter was 2.14, with the Price to Cash per share for the same quarter was set at 0.42.

Trading performance analysis for APYX stock

Apyx Medical Corporation [APYX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.39. With this latest performance, APYX shares gained by 25.12% in over the last four-week period, additionally sinking by -65.47% over the last 6 months – not to mention a drop of -79.38% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for APYX stock in for the last two-week period is set at 60.29, with the RSI for the last a single of trading hit 67.15, and the three-weeks RSI is set at 53.01 for Apyx Medical Corporation [APYX]. The present Moving Average for the last 50 days of trading for this stock 2.33, while it was recorded at 2.53 for the last single week of trading, and 5.02 for the last 200 days.

Apyx Medical Corporation [APYX]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Apyx Medical Corporation [APYX] shares currently have an operating margin of -29.78 and a Gross Margin at +33.14. Apyx Medical Corporation’s Net Margin is presently recorded at -31.27.

Return on Equity for this stock declined to -25.84, with Return on Assets sitting at -21.24.

Apyx Medical Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.10 and a Current Ratio set at 4.10.

Apyx Medical Corporation [APYX]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for APYX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Apyx Medical Corporation go to 15.00%.

An analysis of insider ownership at Apyx Medical Corporation [APYX]

There are presently around $55 million, or 60.90% of APYX stock, in the hands of institutional investors. The top three institutional holders of APYX stocks are: RTW INVESTMENTS, LP with ownership of 3,398,279, which is approximately 0% of the company’s market cap and around 3.40% of the total institutional ownership; COWEN AND COMPANY, LLC, holding 2,854,841 shares of the stock with an approximate value of $7.39 million in APYX stocks shares; and ARCHON CAPITAL MANAGEMENT LLC, currently with $6.98 million in APYX stock with ownership of nearly 1.177% of the company’s market capitalization.

Positions in Apyx Medical Corporation stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 27 institutional holders increased their position in Apyx Medical Corporation [NASDAQ:APYX] by around 1,455,267 shares. Additionally, 33 investors decreased positions by around 1,527,277 shares, while 10 investors held positions by with 18,068,070 shares. The mentioned changes placed institutional holdings at 21,050,614 shares, according to the latest SEC report filing. APYX stock had 7 new institutional investments in for a total of 139,643 shares, while 15 institutional investors sold positions of 485,946 shares during the same period.


Please enter your comment!
Please enter your name here